官方服务：
资源简介：
primary ALL cells from bone marrow aspirates taken two days after in vivo treatment with low-dose methotrexate and mercaptopurine Keywords: other
应用场景：
创建时间：
2018-12-13
相关数据集
Toosendanin Suppresses Acute Myeloid Leukemia by Targeting DDX5/c-Myc Axis to inhibit Protein Synthesis
The treatment of acute myeloid leukemia (AML) continues to be challenged by relapse and resistance, necessitating the development of novel therapeutic strategies. Toosendanin (TSN), a natural product
NIAID Data Ecosystem70
Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia
Nowadays, the simultaneous inhibition of two or more pathways plays an increasingly important role in cancer treatment due to the complex and diverse pathogenesis of cancer, and the combination of the
NIAID Data Ecosystem50
Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in Acute Myeloid Leukemia (RNA-Seq II). Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in Acute Myeloid Leukemia (RNA-Seq II)
Purpose: Compare transcriptional changes between drug treated (gilteritinib, TP-0903) and vehicle in acute myeloid leukemia xenografts. Methods: FLT3-ITD+ MOLM13-Luc+ AML cells were xenografted into N
NIAID Data Ecosystem30
Novel IDH1 Mutant Inhibitors for Treatment of Acute Myeloid Leukemia
This SuperSeries is composed of the SubSeries listed below. Overall design: Refer to individual Series
NIAID Data Ecosystem60
RNA-seq of MV-4-11 or THP-1 cells treated with LSD1 inhibitor INCB059872. RNA-seq of MV-4-11 or THP-1 cells treated with LSD1 inhibitor INCB059872
INCB059872 is a selective irreversible inhibitor of Lysine-Specific Demethylase 1 (LSD1) that is in phase 1 clinical trials in hematopoietic malignancies. LSD1 inhibition can induce differentiation of
NIAID Data Ecosystem30
